Browsing Tag:Biogens

third-member-of-prestigious-fda-panel-resigns-over-approval-of-biogens-alzheimers-drug
A third member of a key advisory body to the Food and Drug Administration has resigned over the agency's controversial decision to approve Biogen's new Alzheimer's drug Aduhelm, CNBC has learned.Dr. Aaron Kesselheim, professor of medicine at Harvard Medical School, said the agency's decision on Biogen was "probably the worst drug approval decision in recent US history," according...
Continue reading
0 Comments
Share
biogens-alzheimers-drug-could-cost-medicare-billions-of-dollars-a-year-report
A pedestrian walks past Biogen Inc. headquarters in Cambridge, Massachusetts on Monday, June 7, 2021.Adam Glanzman | Bloomberg | Getty ImagesBiogen's expensive new Alzheimer's drug Aduhelm could cost Medicare billions of dollars, according to an analysis published Thursday by the nonprofit Kaiser Family Foundation.The Food and Drug Administration on Monday approved the company's drug, the first US...
Continue reading
0 Comments
Share
biogens-alzheimers-drug-approved-by-fda-first-new-therapy-in-nearly-two-decades
The Food and Drug Administration approved Biogen's Alzheimer's drug aducanumab on Monday, making it the first U.S. regulator-approved drug to slow cognitive decline in people with Alzheimer's and the first new drug for the disease in nearly two decades.The FDA's decision was eagerly awaited. The drug, which is marketed under the name Aduhelm, is also expected to generate...
Continue reading
0 Comments
Share